NCT06998082

Brief Summary

Acute hemorrhagic cerebrovascular disease is a life-threatening condition characterized by sudden onset, rapid progression, multiple complications, poor prognosis, and high mortality. It presents a significant public health burden. During surgical interventions, precise risk stratification and effective perioperative management are crucial to mitigating intraoperative and postoperative complications, optimizing disease diagnosis, guiding severity assessment, and refining anesthesia strategies. Continuous real-time evaluation and dynamic perioperative adjustments are essential to minimize the influence of institutional variability and individual clinician-dependent decision-making. By harnessing big data-driven, evidence-based medical approaches, clinicians can enhance diagnostic accuracy and therapeutic precision, addressing a critical challenge in reducing morbidity and mortality in this patient population. This study aims to develop a comprehensive multimodal perioperative database and leverage large language models (LLMs) for the efficient extraction of structured demographic and clinical data throughout the perioperative course. By integrating real-time hemodynamic monitoring parameters, the investigators seek to elucidate the relationship between perioperative hemodynamic patterns and the incidence of postoperative complications affecting major organ systems, including the brain, heart, kidneys, and lungs. The ultimate goal is to construct a multimodal fusion early-warning model capable of real-time, simultaneous prediction of multiple perioperative complications. This AI-driven platform will function as a risk stratification and alert system for organ-specific perioperative complications in patients with acute hemorrhagic cerebrovascular disease. By providing evidence-based insights for optimized perioperative management-encompassing early warning mechanisms, diagnostic support, and individualized therapeutic strategies-the system aims to improve clinical outcomes, reduce perioperative morbidity, and lower overall mortality.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,533

participants targeted

Target at P75+ for all trials

Timeline
32mo left

Started Jul 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress24%
Jul 2025Dec 2028

First Submitted

Initial submission to the registry

May 9, 2025

Completed
22 days until next milestone

First Posted

Study publicly available on registry

May 31, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

July 6, 2025

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Last Updated

May 31, 2025

Status Verified

April 1, 2025

Enrollment Period

2.5 years

First QC Date

May 9, 2025

Last Update Submit

May 28, 2025

Conditions

Keywords

Perioperative ComplicationsArtificial intelligence in MedicineAcute hemorrhagic stroke

Outcome Measures

Primary Outcomes (1)

  • The primary outcome measures were postoperative complications involving the neurological, cardiac, pulmonary, and renal systems in patients with acute hemorrhagic cerebrovascular disease following surgical interventions.

    Within 30 days after surgery

Study Arms (1)

Patients with acute hemorrhagic cerebrovascular disease

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The investigators plan to recruit patients aged 18-80 years with acute hemorrhagic cerebrovascular disease from a minimum of three tertiary Grade A general hospitals.

You may qualify if:

  • Patients aged 18 to 80 years.
  • Diagnosis confirmed by preoperative imaging (CT or MRI) of one of the following conditions:
  • Intracranial aneurysm
  • Arteriovenous malformation (AVM)
  • Hemorrhagic moyamoya disease
  • Cavernous malformation
  • Spontaneous intracerebral hemorrhage
  • Undergoing surgery within seven days of symptom onset.

You may not qualify if:

  • Patients who decline to provide informed consent.
  • Patients enrolled in conflicting clinical studies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Tiantan Hospital

Beijing, Beijing Municipality, 100070, China

Location

Central Study Contacts

ming yu Peng, M.D, Ph.D

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy chief of Department of Anesthesiology

Study Record Dates

First Submitted

May 9, 2025

First Posted

May 31, 2025

Study Start

July 6, 2025

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2028

Last Updated

May 31, 2025

Record last verified: 2025-04

Locations